Roche
RO.SW
#41
Rank
NZ$563.79 B
Marketcap
NZ$708.63
Share price
-0.06%
Change (1 day)
32.49%
Change (1 year)

P/E ratio for Roche (RO.SW)

P/E ratio at the end of 2025: 20.4

According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.6061. At the end of 2025 the company had a P/E ratio of 20.4.

P/E ratio history for Roche from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202520.4-28.11%
202428.360.17%
202317.7-25.96%
202223.9-4.18%
202124.943.67%
202017.4-10.72%
201919.41.8%
201819.1-16.13%
201722.813.42%
201620.1-15.17%
201523.712.39%
201421.148.81%
201314.212.51%
201212.612.65%
201111.213.12%
20109.87-34.15%
200915.026.54%
200811.8-18.81%
200714.6-33.93%
200622.1-19.79%
200527.592.13%
200414.3-62.1%
200337.8-306.17%
2002-18.3-218.88%
200115.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
26.3 27.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.4 3.85%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.7-4.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
23.4 13.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
23.2 12.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
16.7-19.03%๐Ÿ‡ซ๐Ÿ‡ท France
Becton Dickinson
BDX
26.3 27.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
31.7 53.66%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.1-36.55%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.